These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17245837)

  • 1. The future of drug safety: what the IOM report may mean to the emergency department.
    Berger E
    Ann Emerg Med; 2007 Feb; 49(2):193-5. PubMed ID: 17245837
    [No Abstract]   [Full Text] [Related]  

  • 2. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 3. IOM outlines framework for postmarket safety.
    Reinke T
    Manag Care; 2012 Aug; 21(8):10-1. PubMed ID: 22957462
    [No Abstract]   [Full Text] [Related]  

  • 4. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 5. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 6. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 7. IOM panel hears concerns about U.S. drug safety system.
    Young D
    Am J Health Syst Pharm; 2005 Jul; 62(14):1428, 1430-31. PubMed ID: 15998915
    [No Abstract]   [Full Text] [Related]  

  • 8. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 9. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 10. Reviewing case reports and the droperidol warning: FDA response.
    Chang N; Simone A; Schultheis L; Rappaport B
    Anesth Analg; 2003 Nov; 97(5):1542. PubMed ID: 14570686
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to "Can the Institute of Medicine review the FDA?".
    Fineberg HV
    Nat Med; 2005 Jun; 11(6):589. PubMed ID: 15937463
    [No Abstract]   [Full Text] [Related]  

  • 12. The black box warning.
    Abourjaily HM; Rosenberg M
    J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043
    [No Abstract]   [Full Text] [Related]  

  • 13. IOM: congress must reform FDA to improve drug safety.
    Young D
    Am J Health Syst Pharm; 2006 Nov; 63(21):2032, 2034. PubMed ID: 17057032
    [No Abstract]   [Full Text] [Related]  

  • 14. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
    Kuehn BM
    JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
    [No Abstract]   [Full Text] [Related]  

  • 15. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 17. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.
    Crawford LM
    Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087
    [No Abstract]   [Full Text] [Related]  

  • 18. The future of drug safety.
    Breckenridge A
    Clin Pharmacol Ther; 2007 Feb; 81(2):161-3. PubMed ID: 17259942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA and the IOM report.
    Galson SK
    N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
    [No Abstract]   [Full Text] [Related]  

  • 20. The report by the Institute of Medicine and postmarketing surveillance.
    Klein DF
    Arch Gen Psychiatry; 1999 Apr; 56(4):353-4. PubMed ID: 10197831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.